Observational studyEuropean journal of heart failure2018
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
Observational study in European journal of heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 88 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 5 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2025Pooled it
- Pooled it
- The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis.ESC heart failure · 2024Pooled it
- Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease.Journal of nephrology · 2023Pooled it
- Highlights in heart failure.ESC heart failure · 2019Pooled it
- Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Trial
- Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.European heart journal · 2022Trial
- Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.Clinical and translational science · 2022Trial
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.European journal of heart failure · 2020Trial
- Patterns of Evidence-Based Medication Use in Older Adults with Chronic Heart Failure in Slovakia: A Population-Based Study Using the National Health Information Center Database.Drugs & aging · 2026Article
- Mapping the complexity of care in patients with heart disease living with chronic kidney disease.Clinical kidney journal · 2026Article
- Prognostic Impact of Baseline Potassium Abnormalities in Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Cohort Study.Medical sciences (Basel, Switzerland) · 2026Article
- Review
- Comparative effectiveness of sodium zirconium cyclosilicate versus calcium polystyrene sulfonate for patients with heart failure.Heart and vessels · 2026Article
- Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion.Advances in therapy · 2026Article
- Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin-Angiotensin System Inhibitors Therapy.Clinical and translational science · 2026Article
- Correction to: Hyperkalemia in heart failure with reduced ejection fraction: implications and management.Heart failure reviews · 2026Article
- Mineralocorticoid Receptor Antagonist Use in Contemporary Heart Failure Care.Cardiac failure review · 2026Review
- Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management.Heart failure reviews · 2025Review
- Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study.Advances in therapy · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcerns for hyperkalaemia limit the use of mineralocorticoid receptor antagonists (MRAs). The frequency of MRA-associated hyperkalaemia in real-world settings and the extent of subsequent MRA discontinuation are poorly quantified. METHODS AND
resultsObservational study including all Stockholm citizens initiating MRA therapy during 2007-2010. Hyperkalaemias were identified from all potassium (K
conclusionAmong real-world adults initiating MRA therapy, hyperkalaemia was very common and frequently followed by therapy interruption, especially among participants with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.